Buy Eris Lifesciences; target of Rs 1420 Prabhudas Lilladher

Prabhudas Lilladher's research report on Eris Lifesciences

Eris Lifesciences’ (ERIS) Q2FY25 EBITDA was in line with our estimate (Rs2.65bn; 46% YoY). Eris has opted for inorganic route to diversify and scale up existing portfolio. This has been implemented without diluting margins. We expect margins to sustain at +35% as revenue scales up from recent acquisitions, which are currently operating at sub-optimal profitability. The company has multiple growth levers such as broad-based offerings in the derma segment, opportunities in the cardiometabolic market with patent expirations and benefits of operating leverage, as revenue scales up from these acquisitions.

Outlook

Our FY25 and FY26E EBITDA broadly remain unchanged. We maintain ‘BUY’ rating with revised TP of Rs1,420 (valuing at 16x EV/EBITDA on Sep’26E) as we roll forward.

For all recommendations report, click here